Multiple Locations Clinical Trials for Peritoneal Mesothelioma
1. Los Gatos, California
Name of Study:
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy (HIPEC/IPHC)
Study type:
Interventional
Purpose:
Many Cancers. To determine Treatment response to surgical debulking and intra-operative Intraperitoneal Hyperthermic Chemotherapy (IPHC) in patients with the following malignancies.
ClinicalTrials.gov Identifier:
NCT02349958
Status:
Enrolling, started Sept. 2006, completion Sept 2016; Enrollment 200
Location:
Los Gatos, California
Contact:
Heather McAvoy, LVN
408-827-4274
2. The University of Chicago (Chicago, IL)
Name of Study:
Tissue procurement for gastric cancer, gastrointestinal stromal tumors (gist), esophageal cancer, hepatocellular cancer, biliary cancer, neuroendocrine, peritoneal mesothelioma, anal cancer and colorectal cancers in patients undergoing surgery or biopsy
Study type:
Observational
Purpose:
Collect and store tissue and blood samples from patients with many different types of GI cancers and normal tissue and store it to study for molecular testing for current and future protocols.
ClinicalTrials.gov Identifier:
NCT01416714
Status:
Recruiting- Study started in July 2008- completion October 2017; Estimated enrollment 1000
Location:
The University of Chicago, Chicago Illinois
Contact:
Daniel Catenacci M.D.
773-702-7596
Hedy Kindler, M.D.
773-702-0360
3. The University of Chicago (Chicago, IL)
Name of Study:
Pembrolizumab in Treating Patients With Malignant Mesothelioma
Study type:
Interventional
Purpose:
Pembrolizumab is a monoclonal antibody how well it works by blocking a protein called programmed cell death 1 (PD-1) which may stimulate an immune response and kill tumor cells
ClinicalTrials.gov Identifier:
NCT02399371
Status:
Currently Recruiting – March 2015- March 2018; Estimated enrollment 65
Location:
The University of Chicago, Chicago Illinois
Contact:
Hedy Kindler, M.D.
773-702-0360
4. National Cancer Institute (Bethesda, MD)
Name of Study:
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Study type:
Observational, Time Perspective: Prospective
Purpose:
Patients will be followed to determine the course of the disease and record treatment – pts. Undergo sampling of blood, urine, tumor and abnormal body fluids for banking- studies will be performed on the banked material include genetic and genomic studies, establishment of cell cultures and immunologic studies.
ClinicalTrials.gov Identifier:
NCT01950572
Status:
Enrolling- Start date- September 2013- Completion date July 2034; Estimated enrollment 1000
Location:
National Cancer Institute (Bethesda, MD)
Contact:
Lisa A Bengtson, R.N.
240-760-6106
Raffit Hassan, M.D.
301-451-8742
5. National Cancer Institute (Bethesda, MD)
Name of Study:
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
Study type:
Interventional
Purpose:
To study the effectiveness of SS1P plus two drugs that suppress the immune system to treat malignant mesothelioma.
ClinicalTrials.gov Identifier:
NCT01362790
Status:
Start date May 2011 end date May 2018; 75 patients, sponsored by NCI
Location:
National Institute of Health, Bethesda Maryland
Contact:
Yvonne D Mallory, R.N.
301-451-8742
6. National Cancer Institute (Bethesda, MD)
Name of Study:
Reduced Immunogenicity Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
Study type:
Interventional
Purpose:
LMB-100 is a man-made protein. It is attracted to the mesothelin protein. This is found in many tumors, including mesothelioma. But it is found in only a very small number of normal tissues. After binding to mesothelin on tumors, LMB-100 attacks and kills cancer cells. Researchers want to test LMB-100 in people with advanced mesothelioma.
ClinicalTrials.gov Identifier:
NCT02798536
Status:
Enrolling participants- start June 2016- estimated completion date August 2018; Total enrollment 30
Location:
National Institute of Health, Bethesda Maryland
Contact:
Lisa A Bengtson, R.N.
240-760-6106
7. University of Nebraska
Name of Study:
Cancer Research Repository for Individuals With Cancer Diagnosis and High Risk Individuals, and Individuals With No History of Cancer (Control) (iCaRe2)
Study type:
Observational
Purpose:
A study involving multiple cancers objective is to consolidate existing and future disease specific registries with bio specimens bank to provide a resource that fosters and improves the efficiency of cancer- related research and facilitates collaboration among centers
ClinicalTrials.gov Identifier:
NCT02012699
Status:
Study start November 2013 Completion December 2099
Location:
University of Nebraska
Contact:
Whitney Goldner M.D.
402-559-3579
8. Hillman Cancer Center (Pittsburgh, PA)
Name of Study:
aDC1Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
Study type:
Interventional
Purpose:
This trial is to determine the safest dose of a triple combination (chemokine modulatory regimen of CKM) of celecoxib, interferon alpha (IFN), and rintatolimod that can be given with a DC vaccine as treatment of peritoneal surface malignancies after standard of care surgery.
ClinicalTrials.gov Identifier:
NCT02151448
Status:
Enrolling- Start July 2014- Completion date December 2018-; Estimated enrollment 168
Location:
Hillman Cancer Center, Pittsburgh Pennsylvania sponsored by NCI
Contact:
David L. Bartlett, MD
412-692-2852
Natalie Streeter, BA, MSN, RN
412-235-1276
9. California, Colorado, Maryland, Minnesota
Name of Study:
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That is Refractory to Cisplatin and Pemetrexed
Study type:
Interventional
Purpose:
Best dose of drug Methoxyamine when given together with Cisplatin and Pemetrexed – to improve response of standard treatment of mesothelioma.
ClinicalTrials.gov Identifier:
NCT02535312
Status:
Enrolling- Start August 2015- Completion August 2017; Estimated enrollment 58
Location:
National Cancer Institute Sponsored- City of Hope Comprehensive Cancer Center, Duarte California, University of California Davis Comprehensive Cancer Center Sacramento, California, University of Colorado Cancer Center, Aurora, Colorado, University of Maryland/Greenebaum Cancer Center Baltimore Maryland, Mayo Clinic Rochester, Minnesota
Contact:
City of Hope: Marianna Koxzywas, RN
800-826-4673
University of California Davis Comprehensive Cancer Center: Karen L. Kelly
916-734-3089
Mesothelioma Clinical Trial Information
Learn More About Mesothelioma
Did You Know?
Get Help from Experienced Mesothelioma Nurses
Learn more about these experienced mesothelioma nurses by watching the video below. Click here to contact a mesothelioma nurse now.
Learn More About MesoLawyersCare
Watch the video below to learn why MesoLawyersCare is the best choice to represent you and your family after a mesothelioma diagnosis.
Contact MesoLawyersCare Now
If you or a loved one has been diagnosed with mesothelioma, please contact us to see if we can help you get the compensation you deserve from the billions of dollars in asbestos trust funds available now for qualified asbestos victims. With just one call, you can put all our experience and success to work for you.
We have represented thousands of victims of mesothelioma and their families in virtually every State in the country and in decades of work have recovered billions of dollars in financial compensation for our clients.
Call us now at 1-888-568-1177, fill out the form on this page or chat with a live person. The consultation is free and it costs nothing upfront to hire the lawyers behind MesoLawyersCare. We only get paid if you collect a settlement or verdict and you will never receive a bill from us.
Receive a
FREE No Obligation
Legal Consultation Today
Important Notice: We are unable to help if:
- Diagnosis or passing was more than three years ago
- An attorney has already been retained in this matter
“You have all been so wonderful to us, so professional, and always looking out for our best interests in every way. I know it’s a job you do. However, not once did anyone ever make us feel like we did not matter.”